Next Article in Journal
Isolated Late Metastasis from Testicular Seminoma Presenting as a Parotid Gland Mass: Case Report and Review of the Literature
Previous Article in Journal
Aloe vera for Prevention of Radiation-Induced Dermatitis: A Self-Controlled Clinical Trial
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Case Report

Symptomatic Response to Imatinib Mesylate in Cutaneous Mastocytosis Associated with Chronic Myelomonocytic Leukemia

1
Department of Medicine, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
2
Department of Pathology, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(4), 349-353; https://doi.org/10.3747/co.20.1301
Received: 2 May 2013 / Revised: 4 June 2013 / Accepted: 10 July 2013 / Published: 1 August 2013
Mastocytosis is an uncommon disorder defined by increased and abnormal mast cells in one or more tissues. Cutaneous mastocytosis (CM) is limited to the skin, with varying degrees of rash, pruritus, and disfigurement. Systemic mastocytosis (SM) typically involves the bone marrow, sometimes in association with other bone marrow disorders, including chronic myelomonocytic leukemia (CMML). Mastocytosis has been associated with somatic mutations in the gene encoding the tyrosine kinase Kit, leading to identification of Kit as a therapeutic target. The Kit inhibitor imatinib mesylate is approved for aggressive SM. We present an unusual patient with disabling pruritus from telangiectasia macularis eruptiva perstans, a subtype of CM, and CMML, but with no evidence of systemic mast cell disease. She was treated with imatinib and experienced marked improvement in her pruritus. Concomitant CM and CMML have not previously been reported, and the present report is the first of successful imatinib therapy in an adult patient with CM.
Keywords: mastocytosis; chronic myelomonocytic leukemia; imatinib; pruritus; cutaneous; tyrosine kinase inhibitor; tmep mastocytosis; chronic myelomonocytic leukemia; imatinib; pruritus; cutaneous; tyrosine kinase inhibitor; tmep
MDPI and ACS Style

Vannorsdall, E.J.; Collins, J.A.; Chen, Q.C.; Sarai, G.; Baer, M.R. Symptomatic Response to Imatinib Mesylate in Cutaneous Mastocytosis Associated with Chronic Myelomonocytic Leukemia. Curr. Oncol. 2013, 20, 349-353. https://doi.org/10.3747/co.20.1301

AMA Style

Vannorsdall EJ, Collins JA, Chen QC, Sarai G, Baer MR. Symptomatic Response to Imatinib Mesylate in Cutaneous Mastocytosis Associated with Chronic Myelomonocytic Leukemia. Current Oncology. 2013; 20(4):349-353. https://doi.org/10.3747/co.20.1301

Chicago/Turabian Style

Vannorsdall, E.J., J.A. Collins, Q.C. Chen, G. Sarai, and M.R. Baer 2013. "Symptomatic Response to Imatinib Mesylate in Cutaneous Mastocytosis Associated with Chronic Myelomonocytic Leukemia" Current Oncology 20, no. 4: 349-353. https://doi.org/10.3747/co.20.1301

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop